Apparently, quite good news?
»The biomarker results obtained in the study support the further development of HER-096 as well as the planned Phase 2 study to evaluate clinical efficacy. The results provide additional information for the selection of dose levels and the refinement of clinical objectives in future studies, as well as guide the selection of biomarkers for further research. The biomarker results will be presented at upcoming scientific conferences and will be submitted for publication in peer-reviewed scientific journals.«